ICD-10-CM code · FY2027
M13.15 Monoarthritis, not elsewhere classified, hip
Header codeNot billable: use one of the 3 billable codes below
About M13.15
Ask EvidencePulse about arthritis
Answers from the published evidence, with every study linked. The question goes into the box; nothing is sent until you press Ask.
Coding notes for M13.15
No notes of its own; the notes below apply from the codes above it.
Also applies, from M13 Other arthritis
Excludes1 Not coded here: never report these together with this code (use the code given instead).
Chapter 13 notes (apply to every code in it)
Note
- Use an external cause code following the code for the musculoskeletal condition, if applicable, to identify the cause of the musculoskeletal condition
Excludes2 Not part of this condition, but a patient can have both: report both codes when both apply.
- arthropathic psoriasis (L40.5-)
- certain conditions originating in the perinatal period (P04-P96)
- certain infectious and parasitic diseases (A00-B99)
- compartment syndrome (traumatic) (T79.A-)
- complications of pregnancy, childbirth and the puerperium (O00-O9A)
- congenital malformations, deformations, and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
Codes under M13.15 3
Related codes in M13.1
- M13.10 Monoarthritis, not elsewhere classified, unspecified siteBillable
- M13.11 Monoarthritis, not elsewhere classified, shoulderHeader
- M13.12 Monoarthritis, not elsewhere classified, elbowHeader
- M13.13 Monoarthritis, not elsewhere classified, wristHeader
- M13.14 Monoarthritis, not elsewhere classified, handHeader
- M13.16 Monoarthritis, not elsewhere classified, kneeHeader
- M13.17 Monoarthritis, not elsewhere classified, ankle and footHeader
Latest research on arthritis
- Low-dose radiotherapy may be effective as a short-term therapeutic option in knee osteoarthritis
- Guselkumab (Tremfya) strengthens its case for protecting joints in psoriatic arthritis
- 2MM: Pharma Roundup – Pfizer’s $10.5B Innovent oncology partnership, Guselkumab (Tremfya) gains a broader psoriatic arthritis label, Venetoclax (Venclyxto) expands first-line CLL options, and Seladelpar (Livdelzi) advances in primary biliary cholangitis
- Selective serotonin reuptake inhibitors may reduce risk of total joint arthroplasty in osteoarthritis
- #VisualAbstract: Personalised Gait Retraining is an Effective Non-Surgical Treatment for Medial Compartment Knee Osteoarthritis
2MM+
Read the research behind every diagnosis
2MM+ gives you every study summary in full, Classics downloads of the landmark trials, EvidencePulse and HypeCheck, and ad-free reading.
See 2MM+ plans